香港联交所最新资料显示，1月5日，拨康视云-B(02592)股东将股票存入中信证券经纪香港，存仓市值 2.66亿港元，占比6.93%。 拨康视云公告，于2026年1月1日，公司已收到基石投资者之一富策控股有限公司出具的自愿承诺函件， 据此，富策控股已自愿向公司承诺，就其根据相关基石投资协议认购的发售股份(包括任何可转换、可 兑换或可行使为或代表有权收取任何上述证券的任何证券)延长禁售承诺，延长期限自原禁售期届满之 翌日(即2026年1月3日)(包括当日)起至上述日期起6个月届满之日止(即2026年7月2日)，或公司与富策控 股另行协定的较早日期止。 ...

格隆汇1月6日丨根据联交所最新权益披露资料显示，2025年12月30日，中广核电力(01816.HK)获中信证券资产管理有限公司在场内以每股均价2.9394港元增 持3049.4万股，涉资约8963.41万港元。 增持后，中信证券资产管理有限公司最新持股数目为2,036,073,000股，持股比例由17.97%上升至18.24%。 | 股份代號: | 01816 | | --- | --- | | 上市法國名稱: | 中國廣核電力股份有限公司 - H股 | | 日期 (日 / 月 / 年): | 06/12/2025 - 06/01/2026 | | 表格序號 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 賣出或涉及的股 每股的平均價 | | | | 持有權益的股份數目 佔已發行的 有關事件的 | | --- | --- | --- | --- | --- | --- | | | 历营河号 | | | | (請參閱上述 *註解)有投票權股 (日/月/年 | | | | | | | 份自分比 | | CS20251231E00004 | 中信证券资产管理有限公司 | 1101(L) | 30,494 ...

Core Viewpoint - China General Nuclear Power (01816.HK) has seen an increase in shareholding by CITIC Securities Asset Management Co., which raised its stake from 17.97% to 18.24% by purchasing 30.494 million shares at an average price of HKD 2.9394 per share, totaling approximately HKD 89.6341 million [1]. Summary by Category - **Shareholding Increase** - CITIC Securities Asset Management Co. acquired 30,494,000 shares of China General Nuclear Power at an average price of HKD 2.9394 per share [1]. - Following this transaction, CITIC's total shareholding in the company increased to 2,036,073,000 shares, representing 18.24% of the total issued shares [1]. - **Financial Implications** - The total investment made by CITIC Securities in this transaction amounts to approximately HKD 89.6341 million [1].

Group 1 - The core viewpoint of the news is that CITIC Securities has achieved significant results during the "14th Five-Year Plan" period, with substantial growth in various financial metrics and a strong market position [1][2]. - CITIC Securities completed equity financing of 3.1 trillion yuan, bond financing of 56.9 trillion yuan, and mergers and acquisitions totaling 2.4 trillion yuan, with total assets surpassing 2 trillion yuan [1]. - The company has maintained over 600 billion yuan in annual revenue for five consecutive years, with net profit consistently around 200 billion yuan, and a record net profit of 232 billion yuan for the first three quarters of this year [1]. Group 2 - In wealth management, CITIC Securities has served over 17 million clients with assets under management of approximately 15 trillion yuan, and has a buyer advisory scale exceeding 130 billion yuan [2]. - The company aims to transform its services across five dimensions, focusing on creating a comprehensive financial product system and enhancing digital service capabilities [2]. - Since its A-share listing in 2003, CITIC Securities has distributed over 88.7 billion yuan in cash dividends, maintaining a cash dividend ratio above 30% for the past three years [2]. Group 3 - The participating institution in the research, Ruiyuan Fund, focuses on value investment and has managed five funds, with the Ruiyuan Growth Value Mixed A fund showing a 74.03% growth over the past year [3].

Group 1 - The article emphasizes the importance of using authoritative and professional analyst reports for stock trading, highlighting their role in identifying potential investment opportunities [1] Group 2 - The content promotes the services of Jin Qilin analysts, suggesting that their reports are timely and comprehensive, which can assist investors in making informed decisions [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 公司名稱: 中信証券股份有限公司 ("本公司") 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06030 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,620,076,855 | RMB | | 1 RMB | | 2,620,076,855 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 2,620,076,855 | RMB | | 1 RMB | | 2,620,076,855 | | 2. 股份分類 | 普通股 ...

Core Viewpoint - Sichuang Medical Technology Co., Ltd. is facing legal scrutiny for alleged fraudulent issuance of securities and violations of information disclosure, with the case now moving to prosecution stage [1][2][3]. Group 1: Legal Proceedings - The Hangzhou Public Security Bureau has concluded its investigation into Sichuang Medical, confirming clear criminal facts and sufficient evidence, and has transferred the case to the Hangzhou People's Procuratorate for prosecution [1]. - Sichuang Medical has received a notice from the Hangzhou Public Security Bureau requesting evidence related to the case, indicating ongoing legal processes [1]. Group 2: Company Operations - Despite the legal issues, Sichuang Medical claims that its production and operational activities are running normally and that the legal proceedings will not impact its business operations [2]. - The company is committed to cooperating with the legal authorities and aims to protect the legal rights of the company and its shareholders [2]. Group 3: Regulatory Actions - The Zhejiang Securities Regulatory Bureau has proposed administrative penalties against Sichuang Medical for fraudulent issuance and information disclosure violations, including a fine of 81.7 million yuan (approximately 8.17 million) for fraudulent fundraising [3][4]. - The regulatory body has also indicated that the former chairman and general manager, Zhang Lizhong, will face a 10-year market ban due to the severity of the violations [4]. Group 4: Financial Background - Sichuang Medical has raised a total of 3.028 billion yuan (approximately 302.8 million) through five fundraising activities, including an initial public offering and multiple private placements [4]. - The company’s initial public offering raised 986 million yuan (approximately 98.6 million), with net proceeds of 934.08 million yuan (approximately 93.4 million) after expenses [5].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 中信証券股份有限公司 ("本公司") 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06030 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,620,076,855 | RMB | | 1 RMB | | 2,620,076,855 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 2,620,076,855 | RMB | | 1 RMB | | 2,620,076,855 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 ( ...

Group 1 - CITIC Securities maintains a "Buy" rating for Huahong Semiconductor (01347.HK) with a target price of HKD 100, highlighting its leading position in specialty process wafer foundry and strong growth potential from capacity expansion and acquisitions [1] - CITIC Securities also maintains a "Buy" rating for SiHuan Pharmaceutical (00460.HK) with a target price of HKD 1.6, noting rapid growth in its medical aesthetic products and strong sales performance of new regenerative products [1] - GF Securities maintains a "Buy" rating for Yum China (09987.HK) with a target price of HKD 453.62, citing improved same-store sales and growth driven by new product iterations and marketing strategies [1] Group 2 - GF Securities initiates coverage on Laoputang Gold (06181.HK) with a "Buy" rating and a target price of HKD 775.64, emphasizing its leading position in handcrafted gold jewelry and strong growth potential from store expansion [2] - GF Securities initiates coverage on Yue Yuen Industrial (00551.HK) with a "Buy" rating and a target price of HKD 19.99, highlighting its status as the largest athletic shoe manufacturer and expected performance recovery [3] Group 3 - Cinda International maintains a "Buy" rating for Hesai Technology (02525.HK), noting its leadership in the global LiDAR market and significant growth in production and market share [4] - Zhongtai Securities initiates coverage on China Resources Land (01109.HK) with an "Accumulate" rating, reporting strong revenue and profit growth along with a healthy financial structure [5] Group 4 - First Shanghai initiates coverage on Jaxin International Resources (03858.HK) with a "Buy" rating and a target price of HKD 82.4, highlighting its world-class tungsten resources and strong profit growth potential [6] - Kaiyuan Securities initiates coverage on Beautiful Pastoral Medical Health (02373.HK) with a "Buy" rating, emphasizing its differentiated business model and effective customer acquisition strategies [7] Group 5 - CICC maintains an "Outperform" rating for Standard Chartered Group (02888.HK), noting better-than-expected Q2 2025 performance driven by significant growth in non-interest income [8]

Core Insights - In 2025, a total of 116 companies were listed on the A-share market, representing a 16% increase from 100 companies in the same period last year [1] - The net fundraising amount for these 116 newly listed companies reached 122.025 billion yuan, a significant increase of 104.25% compared to 59.743 billion yuan in the previous year [1] - The total fees charged by IPO intermediaries for these companies amounted to 9.156 billion yuan, with underwriting and sponsorship fees accounting for 6.704 billion yuan, legal fees for 0.821 billion yuan, and audit fees for 1.631 billion yuan [1] Segment Analysis Underwriting and Sponsorship Fees - The total underwriting and sponsorship fees ranked by board are as follows: Sci-Tech Innovation Board (21.54 billion yuan), Shanghai Main Board (15.37 billion yuan), Growth Enterprise Market (15.11 billion yuan), Shenzhen Main Board (9.24 billion yuan), and Beijing Stock Exchange (5.78 billion yuan) [2][3] - The average underwriting fee is highest for the Sci-Tech Innovation Board at 11.337 million yuan, while the lowest is for the Beijing Stock Exchange at 2.222 million yuan [4] Legal Fees - The total legal fees ranked by firms are led by Shanghai Jintiancheng (1.14 billion yuan), followed by Beijing Zhonglun (1.05 billion yuan), and Zhejiang Tiance (0.57 billion yuan) [7][8] - The average legal fee is highest for the Sci-Tech Innovation Board at 832.01 thousand yuan, and lowest for the Beijing Stock Exchange at 364.62 thousand yuan [4] Audit Fees - The top three audit firms by total fees are Rongcheng (4.17 billion yuan), Tianjian (2.86 billion yuan), and Lixin (2.19 billion yuan) [10][11] - The average audit fee is highest for the Shanghai Main Board at 1.8518 million yuan, and lowest for the Beijing Stock Exchange at 632.39 thousand yuan [4]